Literature DB >> 22998421

Increasing dwell time of mitomycin C in the upper tract with a reverse thermosensitive polymer.

Agnes J Wang1, Zachariah G Goldsmith, Andreas Neisius, Gaston M Astroza, Olugbemisola Oredein-McCoy, Muhammad W Iqbal, W Neal Simmons, John F Madden, Glenn M Preminger, Brant A Inman, Michael E Lipkin, Michael N Ferrandino.   

Abstract

UNLABELLED: Abstract Background and Purpose: Topical chemotherapy for urothelial cancer is dependent on adequate contact time of the chemotherapeutic agent with the urothelium. To date, there has not been a reliable method of maintaining this contact for renal or ureteral urothelial carcinoma. We evaluated the safety and feasibility of using a reverse thermosensitive polymer to improve dwell times of mitomycin C (MMC) in the upper tract.
MATERIALS AND METHODS: Using a porcine model, four animals were treated ureteroscopically with both upper urinary tracts receiving MMC mixed with iodinated contrast. One additional animal received MMC percutaneously. The treatment side had ureteral outflow blocked with a reverse thermosensitive polymer plug. MMC dwell time was monitored fluoroscopically and intrarenal pressures measured. Two animals were euthanized immediately, and three animals were euthanized 5 days afterward.
RESULTS: In control kidneys, drainage occurred at a mean of 5.3±0.58 minutes. Intrarenal pressures stayed fairly stable: 9.7±14.0 cm H20. In treatment kidneys, dwell time was extended to 60 minutes, when the polymer was washed out. Intrarenal pressures in the treatment kidneys peaked at 75.0±14.7 cm H20 and reached steady state at 60 cm H20. Pressures normalized after washout of the polymer with cool saline. Average washout time was 11.8±9.6 minutes. No histopathologic differences were seen between the control and treatment kidneys, or with immediate compared with delayed euthanasia.
CONCLUSIONS: A reverse thermosensitive polymer can retain MMC in the upper urinary tract and appears to be safe from our examination of intrarenal pressures and histopathology. This technique may improve the efficacy of topical chemotherapy in the management of upper tract urothelial carcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22998421      PMCID: PMC3593688          DOI: 10.1089/end.2012.0211

Source DB:  PubMed          Journal:  J Endourol        ISSN: 0892-7790            Impact factor:   2.942


  16 in total

1.  Investigations on backflow in retrograde pyelography; a roentgenological and clinical study.

Authors:  R KOHLER
Journal:  Acta radiol       Date:  1953       Impact factor: 1.990

2.  The use of a novel reverse thermosensitive polymer to prevent ureteral stone retropulsion during intracorporeal lithotripsy: a randomized, controlled trial.

Authors:  Abhay Rane; Anil Bradoo; Pradeep Rao; Subodh Shivde; Mostafa Elhilali; Maurice Anidjar; Kenneth Pace; John R D'A Honey
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

3.  Instillation of mitomycin C after transurethral resection of bladder cancer impairs wound healing: an animal model.

Authors:  Jack Cheng-Tsung Hou; Steve Landas; Ching Y Wang; Oleg Shapiro
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

4.  Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys.

Authors:  G L Chen; D H Bagley
Journal:  J Urol       Date:  2000-10       Impact factor: 7.450

5.  The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up.

Authors:  D A Tolley; M K Parmar; K M Grigor; G Lallemand; L L Benyon; J Fellows; L S Freedman; K M Grigor; R R Hall; T B Hargreave; K Munson; D W Newling; B Richards; M R Robinson; M B Rose; P H Smith; J L Williams; P Whelan
Journal:  J Urol       Date:  1996-04       Impact factor: 7.450

6.  Antegrade perfusion with bacillus Calmette-Guérin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?

Authors:  Gianluca Giannarini; Thomas M Kessler; Frédéric D Birkhäuser; George N Thalmann; Urs E Studer
Journal:  Eur Urol       Date:  2011-07-27       Impact factor: 20.096

7.  Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney.

Authors:  D S Elliott; J W Segura; D Lightner; D E Patterson; M L Blute
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

8.  13-year experience with percutaneous management of upper tract transitional cell carcinoma.

Authors:  P E Clark; S B Streem; M A Geisinger
Journal:  J Urol       Date:  1999-03       Impact factor: 7.450

9.  Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma.

Authors:  F X Keeley; D H Bagley
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

10.  Preventing migration of stones during fragmentation with thermosensitive polymer.

Authors:  Dianne Sacco; W Scott McDougal; Alexander Schwarz
Journal:  J Endourol       Date:  2007-05       Impact factor: 2.942

View more
  1 in total

Review 1.  The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer.

Authors:  Laura Douglass; Mark Schoenberg
Journal:  Bladder Cancer       Date:  2016-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.